Use of Electronic Medical Records to Ascertain Depth of SEER-Reported Melanomas of Unknown Tumor Thickness | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.39.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
Aug 2011

Use of Electronic Medical Records to Ascertain Depth of SEER-Reported Melanomas of Unknown Tumor Thickness

Author Affiliations

Author Affiliations: Departments of Dermatology (Dr Eide) and Public Health Sciences (Drs Eide and C. C. Johnson, Messrs Jacobsen and Krajenta, and Ms D. Johnson), Henry Ford Hospital, Detroit, Michigan.

Arch Dermatol. 2011;147(8):984-986. doi:10.1001/archdermatol.2011.215

Cancer surveillance is important for monitoring disease trends and survival, forecasting future directions, and appropriately targeting strategies for prevention and screening. In the United States, the Surveillance, Epidemiology and End Results (SEER) Program is charged with maintaining records of all cancers reported annually in their respective populations, including melanoma, which is the sixth most common cancer in the United States.1,2

Despite the rigorous methods applied by the SEER tumor registry, there remain limitations on the completeness of data. Approximately 4% of melanomas in the SEER program have no SEER summary stage, which is different from the American Joint Committee on Cancer (AJCC) stage, and approximately 12% of melanomas reported to SEER annually are missing information on tumor thickness.1,3 An important component of AJCC staging, tumor thickness (aka Breslow thickness) is a key predictor of melanoma survival. These melanomas of unknown thickness represent either incomplete clinical information or inadequate abstracting of existing clinical documentation.4

×